Business
FDA panel knocks down Pfizer, Lilly’s osteoarthritis pain drug in near-unanimous vote – FierceBiotech
After dozens of trials over more than 15 years, Pfizer and Eli Lilly’s osteoarthritis hopeful was poised for an FDA decision in December 2020—that is, until the…
After dozens of trials over more than 15 years, Pfizer and Eli Lillys osteoarthritis hopeful was poised for an FDA decision in December 2020that is, until the agency called a panel of outside experts to chew over the drugs application. That panel came down against the drug in a vote on Thursday because of major safety risks and an inadequate plan to manage them.
The Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 19-1 that a drug safety strategy proposed…
-
Noosa News19 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
Business23 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today
-
General13 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business21 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400